2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
2
Rectal Neoplasms
2
Neoplasms
2
Stomach Neoplasms
1
Post-operative Ileus
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Lung Neoplasms
1
Gallbladder Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Polyps
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Gastric Carcinoma
1
Interventions
pembrolizumab
91
Gemcitabine
56
Nivolumab
50
Cisplatin
39
atezolizumab
37
Carboplatin
30
avelumab
29
enfortumab vedotin
25
Docetaxel
23
Magnetic Resonance Spectroscopy
19
Mitomycin
17
Ipilimumab
17
Paclitaxel
16
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Defecation
×
Clear all
NCT04970472
2026-03-19
MicroBlad
University Hospital, Toulouse
Recruiting
1,000 enrolled